Response Genetics makes McNulty chief operating officer
This article was originally published in Clinica
Michael McNulty is to become chief operating officer of molecular diagnostics firm Response Genetics. From 12 July, Mr McNulty will be responsible for the firm’s strategy and corporate development. Before joining Los Angeles, California-based Response, Mr McNulty worked as general manager, diagnostics at Agilent Technologies. He has also held the role of vice-president, laboratory operations at Berkeley HeartLab, which now known as Celera Diagnostics. Response Genetics is focused on the development of PCR-based tests for detecting non-small cell lung, colorectal and gastric cancers.
You may also be interested in...
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals